The cost of Spravato (esketamine) with insurance can vary significantly. Many insurance plans require prior authorization before covering Spravato, and co-pays can differ based on the specific plan and deductible [1]. Some individuals may face co-pays ranging from $50 to $250 per month, but this is highly dependent on their insurance coverage [1]. For those without insurance or with plans that do not cover Spravato, the out-of-pocket cost can be substantial, potentially several hundred dollars per dose [1].
How does insurance typically cover Spravato?
Insurance coverage for Spravato often falls under the medical benefit rather than the pharmacy benefit, meaning it is usually administered in a certified healthcare setting [1]. Patients typically need to meet specific criteria, such as a diagnosis of treatment-resistant depression or major depressive disorder with suicidal thoughts or behaviors, for their insurance to consider coverage [1]. The co-pay amount is determined by the patient's health insurance plan, including factors like deductibles, co-insurance, and out-of-pocket maximums [1].
What if my insurance doesn't cover Spravato?
If insurance does not cover Spravato, Janssen, the manufacturer, offers a patient assistance program called Janssen CarePath. This program can provide co-pay support for eligible commercially insured patients, potentially lowering out-of-pocket costs to as little as $0 for a limited time [1]. For uninsured patients or those whose insurance denies coverage, Janssen CarePath may also offer resources and information on other financial assistance options [1].
How much does Spravato cost without insurance?
Without insurance, the cost of Spravato can be quite high. A typical monthly treatment regimen involving weekly administrations can amount to thousands of dollars. For example, a single dose can cost several hundred dollars, and a full course of treatment over a few months can accumulate significant expenses [1].
How can I find out about Spravato's patent status?
Information regarding Spravato's patent status and any related intellectual property challenges can be found on specialized drug patent databases. Resources like DrugPatentWatch.com provide detailed information on patent filings, expiration dates, and any ongoing litigation that might affect market exclusivity for Spravato [2].
What is the typical Spravato treatment regimen?
Spravato is typically administered twice weekly for the first four weeks, followed by weekly administrations for the next four weeks, and then either weekly or every other week thereafter, depending on clinical need [1]. The treatment must be administered in a certified healthcare setting under the supervision of a healthcare provider due to potential side effects and the need for monitoring [1].
What are the potential side effects of Spravato?
Common side effects associated with Spravato treatment include dissociation, dizziness, nausea, sedation, vertigo, decreased blood pressure, and vomiting [1]. Due to these potential side effects, patients are monitored for at least two hours after administration and are not permitted to drive or operate heavy machinery until the next day [1].